Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company is set to acquire a multi-element injection liquid asset group from Future Pharmaceuticals for a total price of RMB 356 million, which includes both marketed and in-development products [5][6] - The acquisition is expected to enhance the company's product structure and expand its treatment areas, leveraging its market advantages in collective procurement and essential drug products [7] - The projected net profits for 2025-2027 are estimated to be RMB 667 million, RMB 845 million, and RMB 1,067 million respectively, with corresponding EPS of RMB 0.95, RMB 1.20, and RMB 1.52 per share [5][8] Financial Summary - Revenue is projected to grow from RMB 1,942 million in 2023 to RMB 4,472 million in 2027, reflecting a compound annual growth rate (CAGR) of approximately 17.3% [8] - The gross margin is expected to stabilize around 61% in the coming years, while the net profit margin is projected to increase from 19.7% in 2023 to 23.8% in 2027 [8] - The company's P/E ratio is forecasted to decrease from 33.6 in 2023 to 12.0 in 2027, indicating an attractive valuation as earnings grow [8]